University of Regina welcomes global carbon capture and storage event
The International Carbon Capture and Storage Knowledge Centre, along with the University of Regina, are in the midst of hosting a weeklong program bringing together students and presenters from all around the world.
Organizers of the event say that the presenters talk about current and future carbon capture technologies, economics, policies and regulations.
On the student side, the event had over 200 applicants this year, of which, 50 were chosen to partake.
'We've got 50 students from 31 countries here,' explained Tim Dixon, director and general manager of the International Energy Agency Greenhouse Gas R&D Programme.
'They form teams, and they collaborate, and on the last day they have to present their results. It's actually a competition; we give an award for the best group presentation. As well as getting the knowledge on CCS for themselves, it also forms their professional peer groups that will go with them for the rest of their careers.'
2025 marks the 17th iteration of the CCS Summer School, which after the completion of this week, will have over 800 alumni.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
33 minutes ago
- National Post
Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula
Article content Novel preservative-free CBT-004 eye drop formulation demonstrates statistically significant improvements in conjunctival hyperemia and patient-reported symptoms with excellent safety profile Article content IRVINE, Calif. — Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. Article content Key Phase 2 Results Article content Primary Endpoint Achieved: Article content Both investigated concentrations of CBT-004 demonstrated statistically significant improvements in conjunctival hyperemia compared to vehicle at Day 28, as assessed by an independent reading center using digital imaging. Article content Rapid Onset and Sustained Efficacy: Article content Significant improvements were observed as early as Day 7 with the highest investigated concentration CBT-004 , with benefits persisting through the 28-day treatment period. Article content Significant Symptom Relief: Article content Both CBT-004 concentrations showed statistically significant improvements in five common patient-reported symptoms including burning/stinging, itching, foreign body sensation, eye discomfort, and pain compared to vehicle. Article content Excellent Safety Profile: Article content No treatment-related adverse events were observed. Most adverse events were mild to moderate. No clinically meaningful changes in visual acuity or intraocular pressure were reported. Article content Addressing a Significant Unmet Medical Need Article content Vascularized pinguecula affects millions of Americans and represents a substantial unmet medical need in ophthalmology. This common, benign conjunctival growth can become problematic when it develops abnormal blood vessels and inflammation, which can lead to persistent redness, irritation, pain, and foreign body sensation. Current management options are limited, with many patients relying on off-label corticosteroids or surgical excision, both of which carry significant limitations and potential complications. Article content Study Design and Results Article content The multicenter, randomized, double-masked, vehicle-controlled Phase 2 study enrolled 88 adult patients with vascularized pinguecula and associated conjunctival hyperemia. Participants were randomized to receive one of two concentrations of CBT-004, or vehicle. The primary endpoint was the change from baseline in conjunctival hyperemia at Day 28, as measured by an independent reading center using standardized digital imaging protocols. Article content 'There is a significant unmet need for patients suffering from symptomatic pinguecula, as current therapies are largely off-label and may carry safety concerns with long-term use,' said Dr. John Hovanesian, Clinical Professor of Ophthalmology and recognized key opinion leader in anterior segment disease. 'The results from this trial are exciting, as they demonstrate that a targeted, non- steroidal therapy can meaningfully improve both the clinical signs and symptoms that impact patients' quality of life.' Article content 'As a principal investigator in this study, I was impressed by the consistency and magnitude of improvement in both objective redness and patient-reported discomfort with CBT-004,' commented Dr. Sherif El-Harazi, Medical Director at Global Research Management. 'The safety profile was excellent, and I believe this therapy could represent a meaningful advance for our patients with vascularized pinguecula.' Article content About CBT-004 Article content CBT-004 is a novel, preservative-free topical ophthalmic solution containing a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors and platelet-derived growth factor (PDGF) receptors. The formulation is specifically designed to reduce abnormal blood vessel growth and inflammation associated with vascularized pinguecula while minimizing potential ocular surface toxicity through its preservative- free composition. Article content Next Steps and Regulatory Strategy Article content Based on these positive Phase 2 results, Cloudbreak Pharma Inc. plans to advance CBT-004 into Phase 3 development and initiate discussions with the U.S. Food and Drug Administration (FDA) to establish the regulatory pathway toward potential approval. The company anticipates providing updates on Phase 3 study design and timing in the coming months. Article content Market Opportunity Article content The vascularized pinguecula market represents a significant commercial opportunity with limited therapeutic options. The prevalence of pinguecula increases with age and UV exposure, affecting a substantial portion of the aging population. With no FDA-approved treatments specifically indicated for this condition, CBT-004 has the potential to become a category-defining therapy in this underserved market. Article content About Cloudbreak Pharma Inc. Article content Cloudbreak Pharma Inc. is a clinical-stage ophthalmology company dedicated to developing innovative therapies for ocular surface diseases with high unmet medical need. The company's pipeline focuses on novel treatments targeting inflammation, vascularization, and other pathological processes affecting the ocular surface. Cloudbreak is committed to improving outcomes for patients with challenging eye conditions through scientifically-driven therapeutic development. Article content Forward-Looking Statements Article content This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential therapeutic benefits of CBT-004, the company's clinical development plans, regulatory strategy, and market opportunity. These forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause actual results to differ include, but are not limited to, the uncertainty of clinical trial results, regulatory approval processes, competitive developments, and other risks detailed in the company's filings. The company undertakes no obligation to update these forward-looking statements except as required by law. Article content Article content Article content Contacts Article content Contact Information: Article content Article content Cloudbreak Pharma Inc. Article content Article content
CTV News
8 hours ago
- CTV News
UWindsor six years ahead of climate action target
The University of Windsor reached its 2030 climate action target six years earlier than expected. Since 2019, the university has cut greenhouse gas emissions by 47 per cent. UWindsor President and Vice-Chancellor Robert Gordon said the achievement is one of the most significant environmental milestones in the institution's sustainability. 'It is a true testament to the dedication of our cross-campus operational and academic teams, including the students who helped lead the way,' said Gordon. One contributor to the reduction of emissions was the installation of a hybrid electric-steam chiller in 2023. The machine helped reduce natural gas reliance and lower carbon output. According to UWindsor's vice-president, finance and safety operations, Gillian Heisz, the amount of carbon dioxide equivalent dropped by 12,462 tonnes from 2019 to 2024. 'Internal data reporting shows GHG emissions have dropped from approximately 26,300 tonnes CO₂e in 2019 to 13,838 tonnes CO₂e in 2024,' said Heisz. The university also followed low-carbon design principles in new construction and promoted sustainable transportation as part of sustainability initiatives.
CTV News
9 hours ago
- CTV News
Downtown Montreal is up to six degrees hotter than Mount Royal, study finds
Research led by a Montreal student shows that downtown can be up to six degrees hotter than greener parts of the city. Research led by a Montreal student shows that downtown can be up to six degrees hotter than greener parts of the city — a temperature gap with real consequences for health and equity as climate change intensifies. Johanna Arnet is a master's student at Université du Québec à Montréal (UQAM) and a member of its Chair on Urban Forests. Her research focuses on how spatial and temporal temperature patterns vary within the city, and how urban forests can help mitigate the effects of heat. Using a bicycle with high-precision sensors — including air and surface temperature sensors, a pyranometer to measure solar radiation, and GPS — Arnet has been pedaling through different Montreal neighbourhoods to collect data at human height. 'We're sampling every second, which means we're gathering readings every few metres,' said Arnet, whose project is carried out in collaboration with both UQAM and Concordia University. 'It's very fine scale, and more relevant to human health than satellite imagery, which mostly captures surface temperatures on rooftops.' Arnet said her routes were designed to capture differences in canopy cover and built environment, two major factors influencing local temperatures. One of her new routes, added this summer, goes from downtown Montreal to Mount-Royal Park. 'Along that stretch, we found an average difference of around six degrees, which is quite significant,' she said. Temperatures are recorded between 3 p.m. and 5 p.m., typically the hottest hours of the day in the city. Additional measurements are also taken at night — at least three hours after sunset — when the urban heat island effect tends to peak. Ville-Marie borough looking to make a difference The study is being done in partnership with the Ville-Marie borough and the Quartier des spectacles neighbourhood, both of which are exploring ways to reduce heat through urban greening. 'There's a whole bunch of tree-planting initiatives underway, and they were wondering which areas should be prioritized,' said Arnet. 'This project helps map out the hotter and colder areas in the borough so that decisions can be more targeted.' But cooling dense, downtown areas isn't always simple. In the Quartier des spectacles, Arnet said, the layout changes constantly to accommodate various events such as festivals. Because of this, planting permanent trees isn't always an option. Instead, the neighbourhood has turned to a more flexible solution: mobile greenery. 'They have over 100 trees in pots that can be moved around to work within the changing layout,' said Arnet. 'They even use some of them as road blockers to restrict car access, which is another innovative way to reduce heat without ripping up concrete.' Arnet stressed the importance of mixing strategies — like adding shade structures, green roofs, or green walls — especially in areas where space is limited. The resilience of the city's urban forest is also key, she added, noting the need for species diversity to protect against future pest outbreaks. 'Functional and structural diversity is crucial, trees, shrubs, and ground-level vegetation all play a role,' she said. How heatwaves expose inequality Isabella Richmond is a PhD student in biology at Concordia University researching how urban ecosystems and design can influence heat exposure and health outcomes. 'We define cities by their impervious surfaces, which basically means concrete, and in Montreal that's definitely what comes to mind when you think of downtown,' said Richmond, who is helping with Arnet's project. With fewer trees and more built infrastructure, heat accumulates and radiates through the day and night. Richmond said that a six-degree difference is far from negligible. 'To the human body, that's the difference between comfortable and dangerously hot,' she said. 'Even a half-degree can be felt, so, six degrees is massive.' She pointed to another example: the stark contrast between Park-Extension and the Town of Mount Royal. The two adjacent neighbourhoods show wide differences in canopy cover, housing density, and access to green space — and, as a result, temperature. 'There's a real imbalance in who feels the worst of the heat,' said Richmond. 'Urban design is everything.' The consequences of heat exposure go beyond discomfort. Richmond pointed to studies that have shown links between urban heat and higher risks of cardiovascular and respiratory illness. She noted that wealthier, whiter communities tend to live in cooler areas, a phenomenon she referred to as the 'luxury effect.' 'And the people who live in hotter zones often don't have access to things like air conditioning, either in their homes or even in a vehicle,' she said. 'So not only are they experiencing higher temperatures, but they don't have the same access to relief.' As climate change accelerates, the research team hopes its data will help guide how and where cooling interventions are made and ensure they reach those who need them most.
